JP2018521064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521064A5 JP2018521064A5 JP2018500373A JP2018500373A JP2018521064A5 JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5 JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018500373 A JP2018500373 A JP 2018500373A JP 2018521064 A5 JP2018521064 A5 JP 2018521064A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- kit
- her2 antibody
- cancer
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 17
- 239000000523 sample Substances 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 9
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 9
- 229940125644 antibody drug Drugs 0.000 claims 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 239000013068 control sample Substances 0.000 claims 5
- -1 1H-pyrrolo [2,3-b] pyridin-5-yloxy Chemical group 0.000 claims 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 4
- 239000000611 antibody drug conjugate Substances 0.000 claims 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 2
- 108700041737 bcl-2 Genes Proteins 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150072304 ER2 gene Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021112329A JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189610P | 2015-07-07 | 2015-07-07 | |
| US62/189,610 | 2015-07-07 | ||
| PCT/US2016/041184 WO2017007846A1 (en) | 2015-07-07 | 2016-07-06 | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112329A Division JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521064A JP2018521064A (ja) | 2018-08-02 |
| JP2018521064A5 true JP2018521064A5 (enExample) | 2019-08-08 |
| JP6910339B2 JP6910339B2 (ja) | 2021-07-28 |
Family
ID=56464320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500373A Active JP6910339B2 (ja) | 2015-07-07 | 2016-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
| JP2021112329A Pending JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021112329A Pending JP2021178825A (ja) | 2015-07-07 | 2021-07-06 | 抗ｈｅｒ２抗体−薬物複合体とｂｃｌ−２阻害剤の併用療法 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10898570B2 (enExample) |
| EP (1) | EP3319995B1 (enExample) |
| JP (2) | JP6910339B2 (enExample) |
| KR (2) | KR20240129101A (enExample) |
| CN (2) | CN107922504B (enExample) |
| AU (1) | AU2016290065B2 (enExample) |
| BR (1) | BR112017028012A2 (enExample) |
| CA (1) | CA2990465A1 (enExample) |
| DK (1) | DK3319995T3 (enExample) |
| ES (1) | ES2731377T3 (enExample) |
| HR (1) | HRP20191019T1 (enExample) |
| HU (1) | HUE044139T2 (enExample) |
| IL (1) | IL256451B (enExample) |
| LT (1) | LT3319995T (enExample) |
| MX (1) | MX2018000135A (enExample) |
| PL (1) | PL3319995T3 (enExample) |
| PT (1) | PT3319995T (enExample) |
| RS (1) | RS58823B1 (enExample) |
| SI (1) | SI3319995T1 (enExample) |
| TR (1) | TR201908138T4 (enExample) |
| WO (1) | WO2017007846A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3589661T (lt) | 2017-03-02 | 2024-02-12 | Genentech, Inc. | Adjuvantinis her2 atžvilgiu teigiamo krūties vėžio gydymas |
| CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
| WO2020252015A1 (en) * | 2019-06-10 | 2020-12-17 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| WO2024211811A2 (en) * | 2023-04-05 | 2024-10-10 | Frezent Biological Solutions, Inc. | Methods and compositions for antibody-drug conjugates |
| CN119454975B (zh) * | 2024-12-02 | 2025-10-21 | 中国医学科学院医学实验动物研究所 | 一种药物组合物在治疗癌症中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
| CZ20004224A3 (cs) | 1998-05-15 | 2002-02-13 | Imclone Systems Incorporated | Neradioaktivně značený inhibitor proteinového tyrosinkinázového receptoru |
| DK2283867T3 (da) | 1999-06-25 | 2014-06-10 | Immunogen Inc | Fremgangsmåder til behandling ved anvendelse af anti-ErbB antistof-maytansinoidkonjugater |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| CN109395082A (zh) * | 2000-05-19 | 2019-03-01 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US7795232B1 (en) * | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6790954B2 (en) | 2002-01-29 | 2004-09-14 | Immunogen, Inc. | Mutant Actinosynnema pretiosum strain with increased maytansinoid production |
| WO2004056971A2 (en) * | 2002-12-19 | 2004-07-08 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US7432088B2 (en) | 2003-05-08 | 2008-10-07 | Immunogen Inc. | Methods for the production of ansamitocins |
| US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| SI2644204T1 (sl) * | 2008-03-18 | 2017-08-31 | Genentech, Inc. | Kombinacije konjugata protitelo proti HER2-zdravilo in pertuzumaba |
| AU2014240234B2 (en) * | 2008-03-18 | 2016-10-06 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| PE20120345A1 (es) | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9766249B2 (en) * | 2010-04-19 | 2017-09-19 | Biomarker Strategies, Llc | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| WO2011146568A1 (en) * | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| KR20140048881A (ko) * | 2011-05-09 | 2014-04-24 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 암 치료 조성물 및 방법 |
| CN109939236A (zh) * | 2012-06-08 | 2019-06-28 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| JP6408993B2 (ja) * | 2012-09-07 | 2018-10-17 | ジェネンテック， インコーポレイテッド | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| CN104370905B (zh) * | 2014-10-22 | 2016-06-01 | 南京友杰医药科技有限公司 | Bcl-2抑制剂ABT-199的合成 |
-
2016
- 2016-07-06 CN CN201680040184.1A patent/CN107922504B/zh active Active
- 2016-07-06 RS RS20190727A patent/RS58823B1/sr unknown
- 2016-07-06 PL PL16741212T patent/PL3319995T3/pl unknown
- 2016-07-06 PT PT16741212T patent/PT3319995T/pt unknown
- 2016-07-06 SI SI201630278T patent/SI3319995T1/sl unknown
- 2016-07-06 CN CN202110774906.9A patent/CN113607945B/zh active Active
- 2016-07-06 TR TR2019/08138T patent/TR201908138T4/tr unknown
- 2016-07-06 BR BR112017028012-4A patent/BR112017028012A2/en not_active Application Discontinuation
- 2016-07-06 DK DK16741212.1T patent/DK3319995T3/da active
- 2016-07-06 WO PCT/US2016/041184 patent/WO2017007846A1/en not_active Ceased
- 2016-07-06 CA CA2990465A patent/CA2990465A1/en active Pending
- 2016-07-06 HU HUE16741212A patent/HUE044139T2/hu unknown
- 2016-07-06 ES ES16741212T patent/ES2731377T3/es active Active
- 2016-07-06 LT LTEP16741212.1T patent/LT3319995T/lt unknown
- 2016-07-06 EP EP16741212.1A patent/EP3319995B1/en active Active
- 2016-07-06 MX MX2018000135A patent/MX2018000135A/es unknown
- 2016-07-06 KR KR1020247027710A patent/KR20240129101A/ko not_active Ceased
- 2016-07-06 AU AU2016290065A patent/AU2016290065B2/en active Active
- 2016-07-06 HR HRP20191019TT patent/HRP20191019T1/hr unknown
- 2016-07-06 JP JP2018500373A patent/JP6910339B2/ja active Active
- 2016-07-06 KR KR1020187000356A patent/KR102697939B1/ko active Active
-
2017
- 2017-12-20 IL IL256451A patent/IL256451B/en unknown
- 2017-12-20 US US15/849,018 patent/US10898570B2/en active Active
-
2020
- 2020-12-21 US US17/129,096 patent/US20210213130A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112329A patent/JP2021178825A/ja active Pending
-
2024
- 2024-05-09 US US18/659,241 patent/US20240277838A1/en not_active Abandoned
- 2024-12-17 US US18/984,106 patent/US20250121058A1/en active Pending
-
2025
- 2025-08-08 US US19/294,660 patent/US20250367287A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5844961B2 (ja) | 放射線直腸ｓ状結腸炎を処置するための組成物および方法 | |
| JP2019031506A (ja) | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 | |
| Liu et al. | Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts | |
| JP2018521064A5 (enExample) | ||
| JP2025176093A (ja) | 胃腸間質腫瘍を治療するためのリプレチニブ | |
| Jia et al. | Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity | |
| JP2014132009A5 (enExample) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2012500180A5 (enExample) | ||
| JP2023022190A (ja) | 癌治療 | |
| JP2019530706A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 | |
| Thompson et al. | Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status | |
| Chen et al. | ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer | |
| JP2025134747A (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| Wen et al. | CTNI-12. Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGHT): a phase II platform trial using Bayesian adaptive randomization | |
| Chen et al. | PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer | |
| ES2880444T3 (es) | Combinación de metotrexato y simvastatina para su uso en el tratamiento del osteosarcoma | |
| JP4982377B2 (ja) | 過剰増殖性疾病の治療及び予防のための組成物及び方法 | |
| JP7372740B2 (ja) | 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ | |
| Acton | Antineoplastic Monoclonal Antibodies—Advances in Research and Application: 2012 Edition: ScholarlyBrief |